Clinical Trial Update: The KN510713 Study in Combination With mFOLFIRINOX [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating KN510713 in combination with mFOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• KN510713 (KN-510713)
• mFOLFIRINOX

Snippet

Sponsor: New Cancer Cure-Bio Co.,Ltd. | Conditions: Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1, Phase 2 | Status: RECRUITING